Q3 FY2026 · ended Sep 30, 2026 · Revenue $411.18M, +2.3% YoY · Filed Oct 23, 2026
Integra Lifesciences Holdings Corp (IART) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $411.2 million and net income of $14.9 million. Free cash flow was $85.7 million. As of Sep 30, 2026 it held $311.9 million in cash and investments and $873.2 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- IART (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 917520
- Former names
- INTEGRA LIFESCIENCES CORP (until Mar 31, 1999)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $411.2M | $418.8M | $391.9M | $434.9M | $402.1M |
| Operating income | $18.9M | $19.3M | $11.5M | $23.0M | $11.8M |
| Net income | $14.9M | $4.5M | -$4.6M | -$1.7M | -$5.4M |
| Diluted EPS | $0.19 | $0.06 | -$0.06 | -$0.02 | -$0.07 |
| Operating cash flow | $96.0M | $22.8M | $9.8M | $11.8M | $40.9M |
| Free cash flow | $85.7M | $10.5M | -$5.0M | -$5.4M | $25.8M |
| Total assets | $3.5B | $3.6B | $3.6B | $3.6B | $3.6B |
| Total liabilities | $2.4B | $2.5B | $2.5B | $2.6B | $2.6B |
| Stockholders' equity | $1.1B | $1.0B | $1.0B | $1.0B | $1.0B |
| Cash and investments | $311.9M | $274.1M | $265.5M | $263.7M | $267.9M |
| Total debt | $873.2M | $883.8M | $890.9M | $903.6M | $911.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 23, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Regulation FD disclosure
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 2, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
All 1000 Integra Lifesciences Holdings Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.